A federal court in New York has reportedly dismissed a $6.4B suit against Bristol Myers Squibb (NYSE:BMY) that alleged the ...

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...

BriaCell Therapeutics announced that its Bria-IMT cell therapy, plus an immune checkpoint inhibitor regimen, achieved ...

For the second time in 19 months, a federal judge in New York has dismissed a lawsuit claiming that Bristol Myers Squibb slow ...

District Judge Jesse Furman ruled that the plaintiff, UMB Bank, does not have standing to bring the case against Bristol ...

Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by ...

Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program ...

With a drug in advanced testing for two different indications that have spawned several blockbuster drugs, could Alumis be ...

Among patients with Crohn's disease, anti-TNF therapy failed to achieve remission at 3 years, and high drug concentrations ...

Bristol Myers Squibb won a legal victory as a New York judge dismissed a $6.4 billion lawsuit filed by UMB Bank on behalf of ...

UMB Bank NA filed suit against Bristol-Myers in 2021, alleging that the company intentionally slow-rolled the approval ...